Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

NCT07204418 is registered in ClinicalTrials.gov with Karuna Therapeutics, Inc., a Bristol Myers Squibb company as lead sponsor.

NCT NCT07204418
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07204418 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, 4-part, Open-label Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants
Lead sponsor
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase
Phase 1
Overall status
Recruiting
Start date
October 13, 2025
Completion date
December 3, 2026
Enrollment
56 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers